307 related articles for article (PubMed ID: 36209833)
1. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2.
Antar SA; Saleh MA; Al-Karmalawy AA
Life Sci; 2022 Nov; 309():121048. PubMed ID: 36209833
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro.
Wei Q; Kong N; Liu X; Tian R; Jiao M; Li Y; Guan H; Wang K; Yang P
J Transl Med; 2021 Apr; 19(1):157. PubMed ID: 33874948
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of miR-21-5p by pirfenidone to inhibit fibroblast proliferation in the treatment of acquired tracheal stenosis.
Li W; Huang P; Wei J; Tan S; Liu G; Yang Q; Wang G
Clin Respir J; 2024 Jan; 18(1):e13727. PubMed ID: 38151323
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of pirfenidone-NSAIDs conjugates for the treatment of idiopathic pulmonary fibrosis.
Lu X; Zhu C; Gao Y; Yu Z; Yan Q; Liu Y; Luo M; Shi X
Bioorg Chem; 2024 Feb; 143():107018. PubMed ID: 38071874
[TBL] [Abstract][Full Text] [Related]
5. Role and New Insights of Pirfenidone in Fibrotic Diseases.
Lopez-de la Mora DA; Sanchez-Roque C; Montoya-Buelna M; Sanchez-Enriquez S; Lucano-Landeros S; Macias-Barragan J; Armendariz-Borunda J
Int J Med Sci; 2015; 12(11):840-7. PubMed ID: 26640402
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.
Liu Y; Lu F; Kang L; Wang Z; Wang Y
BMC Pulm Med; 2017 Apr; 17(1):63. PubMed ID: 28420366
[TBL] [Abstract][Full Text] [Related]
7. Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio.
Silva-Gomez JA; Galicia-Moreno M; Sandoval-Rodriguez A; Miranda-Roblero HO; Lucano-Landeros S; Santos A; Monroy-Ramirez HC; Armendariz-Borunda J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768791
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone: A novel hypothetical treatment for COVID-19.
Seifirad S
Med Hypotheses; 2020 Nov; 144():110005. PubMed ID: 32575019
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
Li Z; Liu X; Wang B; Nie Y; Wen J; Wang Q; Gu C
Nephrology (Carlton); 2017 Aug; 22(8):589-597. PubMed ID: 27245114
[TBL] [Abstract][Full Text] [Related]
10. Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren's disease -derived fibroblasts.
Zhou C; Zeldin Y; Baratz ME; Kathju S; Satish L
BMC Musculoskelet Disord; 2019 Mar; 20(1):135. PubMed ID: 30927912
[TBL] [Abstract][Full Text] [Related]
11. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
Hamidi SH; Kadamboor Veethil S; Hamidi SH
Pharmacol Rep; 2021 Jun; 73(3):712-727. PubMed ID: 33880743
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Li Y; Li H; Liu S; Pan P; Su X; Tan H; Wu D; Zhang L; Song C; Dai M; Li Q; Mao Z; Long Y; Hu Y; Hu C
Mol Immunol; 2018 Jul; 99():134-144. PubMed ID: 29783158
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways.
Lv Q; Wang J; Xu C; Huang X; Ruan Z; Dai Y
Mol Med; 2020 May; 26(1):49. PubMed ID: 32448163
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone Attenuates Renal Tubulointerstitial Fibrosis through Inhibiting miR-21.
Bi L; Huang Y; Li J; Yang X; Hou G; Zhai P; Zhang Q; Alhaji AA; Yang Y; Liu B
Nephron; 2022; 146(1):110-120. PubMed ID: 34724669
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
Fujiwara A; Shintani Y; Funaki S; Kawamura T; Kimura T; Minami M; Okumura M
Lung Cancer; 2017 Apr; 106():8-16. PubMed ID: 28285699
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-β1/Smad3 pathway.
Ying H; Fang M; Hang QQ; Chen Y; Qian X; Chen M
J Cell Mol Med; 2021 Sep; 25(18):8662-8675. PubMed ID: 34327818
[TBL] [Abstract][Full Text] [Related]
18. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
Togami K; Kanehira Y; Tada H
Biol Pharm Bull; 2013; 36(10):1525-7. PubMed ID: 24088250
[TBL] [Abstract][Full Text] [Related]
19. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
Yu W; Guo F; Song X
Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
[TBL] [Abstract][Full Text] [Related]
20. Potential treatment for vocal fold scar with pirfenidone.
Kodama H; Kumai Y; Nishimoto K; Toya Y; Miyamaru S; Furushima S; Yumoto E
Laryngoscope; 2018 May; 128(5):E171-E177. PubMed ID: 29171670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
